NCT03983577: Efficacy of Point Of Service Testing in MBC

NCT03983577
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients that have received genetic testing for BRCA1/2 after 2013
https://ClinicalTrials.gov/show/NCT03983577

Comments are closed.

Up ↑